---
layout: default
title: Interferon Beta-1A
parent: 僅模型預測 (L5)
nav_order: 411
evidence_level: L5
indication_count: 10
---

# Interferon Beta-1A
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Interferon Beta-1a: From Undocumented Original Indication to Jeune Syndrome Situs Inversus

## One-Sentence Summary

The evidence pack does not contain original-indication or mechanism-of-action data for Interferon beta-1a (DrugBank DB00060), and the drug is currently **not marketed in Canada** (0 DINs).
The TxGNN model predicts a possible link to **Jeune syndrome situs inversus** (a rare skeletal ciliopathy with visceral transposition) with a score of **97.47%**,
but this ranks at knowledge-graph position #36,121, and **no clinical trials or literature support this specific pairing** — the model's own rationale flags the score as likely embedding-similarity noise rather than a genuine mechanistic signal.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — no license or indication text in evidence pack |
| Predicted New Indication | Jeune syndrome situs inversus |
| TxGNN Prediction Score | 97.47% |
| Evidence Level | L5 |
| Canada Market Status | ✗ Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for Interferon beta-1a in this evidence pack (`original_moa: [Data Gap]`), and no original indication is on record. Based on general pharmacological knowledge captured in the evidence pack's own rationale, interferon beta-1a acts through type I interferon receptor–mediated antiviral and immunomodulatory signaling.

Jeune syndrome situs inversus is a rare congenital ciliopathy characterized by skeletal dysplasia and abnormal visceral organ positioning — a structural/developmental disorder, not an immune- or virus-mediated condition. The evidence pack's repurposing rationale explicitly states there is **no known pathway relationship** between interferon beta-1a's mechanism and this disease, and assesses the unusually high TxGNN score (0.975) as most likely reflecting knowledge-graph embedding similarity noise rather than a real mechanistic inference.

Given the absence of any supporting clinical trials or literature (confirmed by three independent zero-result queries against ClinicalTrials.gov, ICTRP, and PubMed — query IDs 2–4 in the query log), this prediction should be treated as a low-confidence model artifact rather than a credible repurposing hypothesis at this time.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction carries a high TxGNN similarity score but zero corroborating clinical or literature evidence (L5), and the evidence pack's own mechanistic assessment identifies no plausible biological pathway between interferon beta-1a and this rare structural/developmental syndrome — most consistent with a knowledge-graph noise artifact rather than a testable hypothesis.

**To proceed, the following is needed:**
- Mechanism of action (MOA) data from DrugBank (currently `[Data Gap]`, High severity gap DG002)
- TFDA/regulatory label warnings and contraindications (currently `[Data Gap]`, **Blocking** gap DG001 — required before any S1 safety screening)
- Original indication and Canada licensing status, since the drug currently shows 0 DINs and "not marketed"
- Preclinical or mechanistic studies establishing a plausible pathway between type I interferon signaling and ciliopathy/skeletal dysplasia biology, before this candidate can advance beyond S0
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

